Cellmid Limited (ASX:CDY) will be convening the 5th Midkine Symposium in Munich, Germany between 3rd and 5th May 2018.
The symposium will be a global meeting of key opinion leaders, clinicians and research scientists involved in midkine (MK) research.
READ: Cellmid strengthens its position in hair and skin care market with leading anti-ageing product
The event follows on the success of the previous four scientific meetings on midkine held in Sydney (2010), Istanbul (2012), Kyoto (2014) and Budapest (2016).
Assessing midkine antibodies in chronic heart failure
Midkine is a promising molecule in drug development. It is a heparin-binding growth factor that promotes cell growth, survival, differentiation and cell migration.
It is almost undetectable in healthy adults, however, is upregulated as part of the pathogenesis (development) of certain chronic diseases.
Munich has been chosen for the symposium as it is the home Ludwig Maximilian University (LMU), where researchers are currently assessing Cellmid’s midkine antibodies in a model of chronic heart failure.
The research at LMU is the subject of a recently filed patent application by Cellmid and is expected to deliver vital data and add to the company’s already substantial midkine asset portfolio.
Promoting interactions between midkine researchers
The symposium will host delegates from twelve countries with expertise in various therapeutic and diagnostic fields and will enhance interactions between leading researchers within the midkine community.
Previous meetings resulted in a number of collaborations that continue to provide vital progress for Cellmid’s therapeutic programs including the recently completed clinical studies carried out at the University of Gothenburg, Sweden.
The study in Sweden demonstrated that midkine is associated with prostate cancer progression and treatment resistance.
Symposium to be led by Dr Ludwig Weckbach
The symposium will be hosted by the team led by clinician scientist Dr Ludwig Weckbach, Cellmid’s research partner based at the Biomedical Center and Department of Cardiology, LMU.
Dr Weckbach will be welcoming symposium delegates as well presenting his group’s innovative discoveries demonstrating the clinical potential of therapeutic antibodies targeting midkine for chronic heart failure.